Northrop Grumman (NOC) — Company Research

Last Updated: 4 June 2026

Northrop Grumman is one of the five large US defence primes, built around stealth aircraft, missile defence, military space and battlefield electronics. The company is the prime contractor on two of the most important US modernisation programmes of the decade — the B-21 Raider stealth bomber and the Sentinel intercontinental ballistic missile — and it carries a record backlog of roughly $96 billion. FY2025 (year ended 31 December 2025) sales rose 2 percent to $42.0 billion, with GAAP diluted EPS of $29.08 and free cash flow of $3.3 billion. Momentum picked up sharply in the first quarter of 2026, when the prior-year B-21 loss provision dropped out of the comparison and diluted EPS jumped 85 percent to $6.14. This report walks through the business, the numbers and the risks, using only figures drawn from Northrop Grumman's own filings and press releases.

1. Company Snapshot

2. Bull & Bear Case

Bull Case

• Record backlog underpins visibility: Backlog of $95.6 billion at the end of Q1 2026, on a full-year 2025 book-to-bill of 1.10, gives multi-year revenue cover across all four segments.
• Two generational franchise programmes: Northrop is sole prime on the B-21 Raider stealth bomber and the Sentinel ICBM, both core to US nuclear and conventional modernisation and both ramping into higher-rate production.
• Margin recovery underway: Q1 2026 segment operating margin rose to 10.8 percent from 6.0 percent a year earlier as the prior-year $477 million B-21 loss provision dropped out, and management guides full-year segment income of $4.85–$5.0 billion.
• Strong cash generation and shareholder returns: FY2025 free cash flow of $3.3 billion grew 26 percent, the third straight year of at least 25 percent growth, funding a rising dividend and buybacks.

Bear Case

• Heavy dependence on the US government: US Government customers represent the large majority of sales, leaving Northrop exposed to continuing resolutions, shutdowns, budget caps and shifting procurement priorities.
• Fixed-price programme risk: The 2025 B-21 loss provision is a reminder that fixed-price development contracts can absorb large unrecoverable cost growth when inflation, labour or supply chains move against the company.
• Space Systems softening: Q1 2026 Space sales fell 3 percent and operating income 17 percent on the Next Generation Interceptor wind-down and a $71 million GEM 63XL launch-anomaly charge.
• Premium-to-growth valuation: With low-single-digit organic growth, the shares price in continued flawless execution; any programme slip or budget shock leaves little cushion.

3. Business Segments

Northrop Grumman reports through four operating segments. The table shows FY2025 sales and each segment's share of total segment sales (before intersegment eliminations of roughly $2.3 billion).

4. Business Model & Moat

How it makes money. Northrop earns the bulk of its revenue from long-cycle US Government contracts — a mix of cost-reimbursable and fixed-price work spanning development, production and sustainment. Revenue converts from a contracted backlog over many years, which smooths sales but means margins hinge on disciplined cost estimation.

Where the moat comes from. The barriers to entry are extreme: classified clearances, decades of programme heritage, irreplaceable engineering talent, and sole-source positions on franchises such as the B-21 and Sentinel that no competitor can realistically replicate. Switching costs for the customer are effectively prohibitive once a platform is in production.

What can erode it. The same government concentration that protects the moat also caps it: pricing is negotiated, programmes can be re-scoped or cancelled, and fixed-price development exposes the company to cost-growth it cannot always recover, as the B-21 charge demonstrated.

5. Financial Health

All figures below are taken from Northrop Grumman's earnings releases and annual report. The annual table runs through the most recently completed fiscal year, FY2025.

"Adjusted EPS" above is Northrop's MTM-adjusted (transaction-adjusted in 2021–2022) diluted EPS, which removes the non-operational mark-to-market pension gain or loss. GAAP EPS is volatile because the mark-to-market adjustment is booked in the fourth quarter each year — it lifted 2021 and 2025 and depressed 2023, which also carried a $1.56 billion pre-tax B-21 charge.

*Northrop records its full-year mark-to-market pension adjustment in the fourth quarter, so Q4 GAAP EPS includes the year's MTM benefit; the Q4 GAAP figure is derived as full-year GAAP EPS less the first three quarters. For the first three quarters of 2025 there is no MTM item, so adjusted and GAAP EPS are the same.

6. Valuation

Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.

7. Growth Drivers

The clearest driver is the B-21 Raider. In early 2026 Northrop reached agreements with the US Air Force to expand B-21 production capacity by roughly 25 percent, supported by about $4.5 billion of appropriated funding, moving the programme from development toward higher-rate production with first basing targeted for 2027. The Sentinel ICBM is a second long-duration driver as it continues to ramp through Defense Systems and Space Systems.

Beyond the franchises, demand is broad: Mission Systems is ramping restricted airborne radar and marine programmes, Defense Systems is growing on tactical solid rocket motors and the Integrated Battle Command System, and a heightened global threat environment is lifting munitions and missile-defence orders. Management guides 2026 sales of $43.5–$44.0 billion and free cash flow of $3.1–$3.5 billion. You can track the wider sector and macro backdrop on the ChartsView Live Charts and Economic Calendar pages.

8. Peer Comparison

9. Insider Activity

Recent Form 4 filings show routine sales by Northrop executives and directors under pre-arranged Rule 10b5-1 trading plans; no open-market insider purchases were reported in the period. Chair and Chief Executive Officer Kathy Warden made no reported open-market transactions in the period covered below.

10. Key Risks

• Government dependence (Macro/Regulatory): The large majority of sales are to the US Government; continuing resolutions, a prolonged shutdown, debt-ceiling stand-offs or budget cuts could delay funding and payments.
• Fixed-price cost growth (Operational): Fixed-price development contracts such as the B-21 can absorb unrecoverable cost growth from inflation, labour shortages and supply-chain disruption.
• Programme execution and EAC adjustments (Operational): Earnings rely on contract cost estimates; unfavourable estimate-at-completion adjustments, like the GEM 63XL charge, can hit segment margins.
• Supply chain and labour (Operational): Availability and pricing of critical materials, components and cleared talent remain constraints on the production ramp.
• Pension and mark-to-market volatility (Financial): Year-end mark-to-market pension remeasurement can swing GAAP earnings materially in either direction.

11. Recent Developments

• 21 Apr 2026 — Q1 2026 results. Sales rose 4 percent to $9.9 billion, operating margin reached 10.0 percent and diluted EPS climbed 85 percent to $6.14; the company reaffirmed full-year guidance.
• 21 Apr 2026 — B-21 production ramp. Northrop confirmed agreements with the US Air Force to increase B-21 production capacity and accelerate Sentinel initial operating capability, including the sale of a company-owned test aircraft to speed deliveries.
• 15 Apr 2026 — B-21 aerial refuelling. The US Air Force released imagery confirming the B-21 had been refuelled in flight, underlining rapid flight-test progress toward 2027 basing.
• 27 Jan 2026 — FY2025 results. Full-year sales of $42.0 billion, GAAP EPS of $29.08, free cash flow of $3.3 billion and a record backlog of $95.7 billion.

12. Key Dates

• 21 Jul 2026 — Expected Q2 2026 earnings release.
• 01 Jun 2026 — Most recent quarterly dividend ex-dividend date.
• 27 Jan 2026 — Fourth-quarter and full-year 2025 results released.
• 21 Apr 2026 — First-quarter 2026 results released.

Discuss this company with other investors on the ChartsView Forum.

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal f